Abdulrahman Al Hadhrami

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Randomized Controlled Trial

Squamous Cell Carcinoma

Gas Chromatography

Top Venues

Current drug targets

Endocrine, metabolic & immune disorders drug targets

This page only lists publications with an associated author ORCID identifier.

Publications

Khalid Al Balushi, Abdulrahman Al Hadhrami, Hamdan Al Balushi, Abdullah Al Lawati, Srijit Das
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma. Current drug targets 25 (3) (2024)
Khalid Al Balushi, Abdulrahman Al Hadhrami, Hamdan Al Balushi, Abdullah Al Lawati, Srijit Das
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma. Current drug targets 25 (3) (2024)
Abdullah Al Lawati, Lubna Al Hashmi, Husain Al Aswami, Abdulrahman Al Hadhrami, Sok Kuan Wong, Srijit Das, Srinivasa Rao Sirasanagandla
Deleterious Biological Effects of Endocrine Disruptors: An Insight into Human Health Risks. Endocrine, metabolic & immune disorders drug targets (2024)
Khalid Al Balushi, Abdulrahman Al Hadhrami, Hamdan Al Balushi, Abdullah Al Lawati, Srijit Das
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma. Current drug targets 25 (3) (2024)
Khalid Al Balushi, Abdulrahman Al Hadhrami, Hamdan Al Balushi, Srijit Das, Abdullah Al Lawati
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma. Current drug targets (2023)